Skip to main content
SpringerLink
Log in

Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

Neuroleptic malignant syndrome (NMS) is one of the most serious adverse reactions to antipsychotic medications. We accumulated data on Japanese NMS patients and, in a study designed to examine the effects of drug metabolism on the occurrence of NMS, tested the possibility of association between NMS and CYP2D6 polymorphisms.

Methods

We studied 53 patients who had experienced NMS and 112 healthy individuals. We determined what drugs the patients with NMS had been given and retrospectively identified candidates for drugs causing NMS. We screened the prevalence of CYP2D6 genotypes using polymerase chain reaction and restriction fragment length polymorphism analyses.

Results

The prevalence of *5 alleles in the group of all patients with NMS was higher than that in the controls, though this difference was not statistically significant (10.4% vs. 5.4%; P = 0.107; odds ratio (OR) 2.05; 95% confidence interval (CI) 0.87–4.80). No association was found between the frequency of *10 alleles and the occurrence of NMS. We found *4 and duplicated alleles in only one patient each among the patients with NMS. A total of 29 patients appeared to have developed NMS as a result of having taking CYP2D6 substrates. The prevalence of *5 alleles in these 29 patient was significantly higher than that in the controls (15.5% vs. 5.4%; P = 0.020; OR 3.25; 95% CI 1.30–8.13).

Conclusion

Our findings suggest that the CYP2D6*5 allele is likely to affect vulnerability to development of NMS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kawanishi C (2006) Pharmacogenetic aspects of neuroleptic malignant syndrome. Curr Pharmacogenomics 4:113–119

    Article  CAS  Google Scholar 

  2. Caroff SN, Mann SC (1993) Neuroleptic malignant syndrome. Med Clin North Am 77:185–202

    PubMed  CAS  Google Scholar 

  3. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, and Sidhom T (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464–470

    PubMed  CAS  Google Scholar 

  4. Caroff SN, Mann SC, Campbell EC (2000) Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 30:314–321

    Google Scholar 

  5. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464–470

    Article  PubMed  CAS  Google Scholar 

  6. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111–122

    Article  PubMed  CAS  Google Scholar 

  7. Kawanishi C, Furuno T, Onishi H, Sugiyama N, Suzuki K, Matsumura T, Ishigami T, Kosaka K (2000) Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiat Genet 10:145–147

    Article  CAS  Google Scholar 

  8. Nishida Y, Fukuda T, Yamamoto I, Azuma J (2000) CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of *10. Pharmacogenetics 10:567–570

    Article  PubMed  CAS  Google Scholar 

  9. Scordo MG, Spina E (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3:201–218

    Article  PubMed  CAS  Google Scholar 

  10. Iwahashi K (1994) CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol Psychiatry 36:780–782

    Article  Google Scholar 

  11. Kawanishi C, Shimoda Y, Fujimaki J, Onishi H, Suzuki K, Hanihara T, Sugiyama N, Kosaka K (1998) Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 160:102–104

    Article  PubMed  CAS  Google Scholar 

  12. Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Suzuki K, Hirayasu Y (2005) CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: Preliminary report. Psychiatry Clin Neurosci 59:504–507

    Article  PubMed  CAS  Google Scholar 

  13. Pope GH, Keck PE, McElroy SL (1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143:1227–1233

    PubMed  Google Scholar 

  14. Kawanishi C, Hanihara T, Maruyama Y, Matsumura T, Onishi H, Inoue K, Sugiyama N, Suzuki K, Yamada Y, Kosaka K (1997) Neuroleptic malignant syndrome and hydroxylase gene mutations: No association with CYP2D6A or CYP2D6B. Psychiatr Genet 7:127–129

    Article  PubMed  CAS  Google Scholar 

  15. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410–418

    Article  PubMed  CAS  Google Scholar 

  16. Lundqvist E, Johanson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and method for detection of duplicated CYP2D6 genes. Gene 226:327–338

    Article  PubMed  CAS  Google Scholar 

  17. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351–355

    Article  PubMed  CAS  Google Scholar 

  18. Wennerholm A, Johansson I, Massele AY, Jande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, Gustafsson L (1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: analysis of the CYP2D6 genotype and phenotype. Pharmacogenetics 9:707–714

    Article  PubMed  CAS  Google Scholar 

  19. Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y (1977) Malignant neuroleptic syndrome: its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn 31:565–576

    Google Scholar 

  20. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA (1989) Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 46:914–918

    PubMed  Google Scholar 

  21. Sachdev P, Mason C, Hadzi-Pavlovic D (1997) Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 154:1156–1158

    PubMed  CAS  Google Scholar 

  22. Berardi D, Amore M, Keck PE Jr, Troia M, Dell’Atti M (1998) Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 44:748–754

    Article  PubMed  CAS  Google Scholar 

  23. Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M (1998) Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 18:349–351

    Article  PubMed  CAS  Google Scholar 

  24. Deuschl G, Oepen G, Hermle L (1987) Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 20:168–170

    PubMed  CAS  Google Scholar 

  25. Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y (1997) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 41:1222–1224

    Google Scholar 

  26. Caroff SN, Mann SC (1998) Neuroleptic malignant syndrome. Psychopharmacol Bull 24:25–29

    Google Scholar 

  27. Wells AJ, SommiRW, Crismon L (1988) Neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm 22:475–480

    PubMed  CAS  Google Scholar 

  28. Lazarus AL, Moore KE, Spinner NB (1991) Recurrnt neuroleptic malignant syndrome associated with inv dup (15) and mental retardation. Clin Genet 39:65–67

    Article  PubMed  CAS  Google Scholar 

  29. Mahendran R, Winslow M, Lim D (2000) Recurrent neuroleptic malignant syndrome. Aust N Z J Psychiatry 34:699–700

    Article  PubMed  CAS  Google Scholar 

  30. Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I, Sjoqvist F (2000) CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 56:679–683

    Article  PubMed  CAS  Google Scholar 

  31. Ellingrod VL, Schultz SK, Arndt S (2000) Association between cytochrome P450 2D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 10:9–11

    PubMed  CAS  Google Scholar 

  32. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S (1998) Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 32:101–106

    Article  PubMed  CAS  Google Scholar 

  33. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, Abe K (1998) Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 32:107–113

    Article  PubMed  CAS  Google Scholar 

  34. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM (1997) Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 131:174–179

    Article  PubMed  CAS  Google Scholar 

  35. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31–34

    Article  PubMed  CAS  Google Scholar 

  36. Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, Kubota T, Iga T, Takarada Y, Vries R, Kaneko S (2003) Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 25:287–293

    Article  PubMed  CAS  Google Scholar 

  37. Someya T, Shimoda K, Suzuki Y, Sato S, Kawashima Y, Hirokane G, Morita S, Yokono A, Takahashi S (2003) Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacol 28:1501–1505

    Article  CAS  Google Scholar 

  38. Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004) Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Mol Psychiatry 9:293–298

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by a Grant-in-Aid for Scientific Research (No. 16790698) from the Ministry of Education, Science, Sports, and Culture, Japan.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236–0004, Japan

    Daiji Kato, Chiaki Kawanishi, Ikuko Kishida, Taku Furuno, Kyoko Suzuki & Yoshio Hirayasu

  2. Department of Psycho-oncology, Saitama Medical University Hospital, 38 Morohongo Moroyama-machi, Iruma-gun, Saitama, 350–0495, Japan

    Hideki Onishi

Authors
  1. Daiji Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiaki Kawanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ikuko Kishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Taku Furuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyoko Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideki Onishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshio Hirayasu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chiaki Kawanishi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kato, D., Kawanishi, C., Kishida, I. et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 63, 991–996 (2007). https://doi.org/10.1007/s00228-007-0355-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0355-8

Keywords

Search

Navigation